Electromed, Inc. (ELMD) Files Form 4 Insider Buying : Oak Partners, Llc Red Buys 67,531 Shares

Electromed, Inc. (ELMD): Oak Partners, Llc Red , 10% owner of Electromed, Inc. purchased 67,531 shares on May 13, 2016. The Insider buying transaction was reported by the company on May 17, 2016 to the Securities and Exchange Commission. The shares were purchased at $3.73 per share for a total value of $252,561.23 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 13, 2016, Oak Partners, Llc Red (10% owner) purchased 78,082 shares at $3.84 per share price.On Nov 18, 2015, William Eckles (director) purchased 60,000 shares at $2.11 per share price.Also, On Nov 18, 2015, Kathleen Skarvan (CEO) purchased 5,000 shares at $2.00 per share price.On Mar 18, 2015, Stephen H. Craney (director) purchased 9,900 shares at $2.35 per share price.

Electromed (ELMD) witnessed a volatile trading activity on Monday May 16, 2016 and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $3.7 and reached the intraday high at $3.79. The bulls started the profit booking and pushed the shares to intraday low of $3.66. The trading session was marked by a volume range of 59,869 shares exchanging hands. The 52-week high of the shares is $5.2 and the 52-week low is $1.55. The market cap of the company stands at $31 M and there are 81,87,112 shares in public circulation.

Electromed Money Flow Index Chart

Electromed Inc. is a pharmaceutical company. The Company manufactures markets and sells products that provide airway clearance therapy including the SmartVest Airway Clearance System (SmartVest System) includes its newest generation SmartVest SQL and previous generation SV2100 and related products to patients with compromised pulmonary function. SmartVest SQL was designed developed and cleared by the FDA in December of 2013. The SmartVest System has been approved by the United States Food and Drug Administration (FDA) to treat the condition of excess lung secretions. It may be prescribed to patients suffering from cystic fibrosis chronic obstructive pulmonary disease muscular dystrophy post-surgical airway complications and a variety of other diseases and conditions associated with impaired lung and airway capacity. During the second half of fiscal year 30 June 2014 the Company launched next generation SmartVest System and the SmartVest SQL to the domestic homecare market.

Leave a Reply

Electromed - Is it time to Sell?

Top Brokerage Firms are advising their investors on Electromed. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.